Published on 17/12/2025
Developing Regulatory Strategies for ATMPs in Emerging Markets: Insights for 2025
Introduction to ATMPs in Emerging Markets
Advanced Therapy Medicinal Products (ATMPs) — including cell therapies, gene therapies, and tissue-engineered products — are rapidly expanding into emerging markets such as India, Brazil, China, and South Korea. While these markets offer vast opportunities for patient access and innovation, they also present unique regulatory, affordability, and infrastructure challenges. Unlike established markets where the FDA and EMA provide mature frameworks, emerging economies often operate under evolving or hybrid guidelines influenced by WHO and ICH standards.
By 2025, global biopharma companies are increasingly designing dedicated regulatory strategies for ATMPs in emerging markets to balance compliance, affordability, and scalability. For RA professionals, these regions demand customized approaches that integrate global best practices with local regulatory nuances.
Key Concepts in Emerging Market ATMP Regulation
Several concepts define ATMP regulatory strategies in emerging markets:
- Local Adaptation: Tailoring global ATMP data packages to meet local authority requirements.
- Hybrid Guidelines: Emerging markets often adapt EMA or FDA guidance with local modifications.
- Affordability and Access: Regulatory approvals often linked with pricing, reimbursement, or patient support programs.
- Technology Transfer: Local manufacturing encouraged to reduce costs
These elements shape the strategic approach required for successful ATMP market entry.
Regional Regulatory Frameworks
Emerging economies have established or are developing ATMP frameworks:
- India (CDSCO): The New Drugs and Clinical Trial Rules, 2019 provide a pathway for stem cell and gene therapy approvals, supported by ICMR guidelines.
- China (NMPA): The NMPA issued Guidelines for Cell Therapy Products in 2022, emphasizing GMP compliance and local clinical data.
- Brazil (ANVISA): Resolution RDC 338/2020 established ATMP regulatory requirements with strong focus on quality and pharmacovigilance.
- South Korea (MFDS): The Act on Safety of Advanced Regenerative Medicine governs ATMP development and conditional approvals.
- Other Markets: Saudi Arabia’s SFDA and South Africa’s SAHPRA are drafting ATMP-specific guidelines influenced by EMA frameworks.
These frameworks demonstrate increasing regulatory maturity but require tailored compliance strategies.
Processes and Workflow for ATMP Market Entry
A structured workflow supports ATMP regulatory strategy in emerging markets:
- Regulatory Intelligence: Conduct market-specific regulatory analysis and engage with local authorities.
- Early Engagement: Seek scientific advice or pre-submission meetings with CDSCO, NMPA, ANVISA, or MFDS.
- Dossier Localization: Adapt CTD/eCTD modules to include local clinical and pharmacovigilance data.
- Clinical Development: Conduct bridging or local clinical trials where required.
- Manufacturing Strategy: Partner with local facilities for GMP-compliant production and distribution.
- Approval Pathway: Submit applications aligned with national frameworks while leveraging global data.
- Post-Approval Commitments: Establish local pharmacovigilance programs and patient registries.
This workflow ensures regulatory compliance while addressing affordability and infrastructure constraints.
Case Study 1: Gene Therapy Approval in China
Case: A multinational biotech sought approval for a gene therapy targeting inherited retinal disease in China.
- Challenge: NMPA required local clinical trial data despite global Phase III results.
- Action: Company conducted a bridging trial with smaller cohorts and real-world data integration.
- Outcome: NMPA granted conditional approval with mandatory long-term registry participation.
- Lesson Learned: Local data generation is often essential for emerging market approvals.
Case Study 2: CAR-T Therapy in Brazil
Case: ANVISA evaluated a CAR-T therapy for leukemia in 2023.
- Challenge: Infrastructure limitations for handling autologous therapies.
- Action: Company partnered with local hospitals for GMP-compliant cleanrooms and staff training.
- Outcome: Approval granted with post-market monitoring conditions.
- Lesson Learned: Local partnerships and capacity building are critical in emerging markets.
Tools, Templates, and Systems for Emerging Market Compliance
RA professionals rely on structured resources to manage ATMP approvals in emerging economies:
- Regulatory Checklists: Customized per country for submission requirements.
- CTD/eCTD Localization Templates: Modules adapted to local regulatory authority expectations.
- Pharmacovigilance Systems: Integrated platforms aligned with PvPI (India), ANVISA, and NMPA requirements.
- Partnership Models: Collaboration templates for joint ventures with local GMP facilities.
- Cost–Benefit Analysis Tools: Strategic evaluation of pricing, reimbursement, and patient support programs.
These resources streamline market entry while reducing regulatory risks.
Common Challenges and Best Practices
ATMPs in emerging markets face persistent challenges:
- Infrastructure Gaps: Limited GMP facilities and supply chain capabilities.
- Regulatory Uncertainty: Guidelines often evolving and inconsistently implemented.
- Affordability Issues: High costs limit patient access, with regulators linking approvals to access programs.
- Data Requirements: Local bridging trials frequently required despite global data availability.
Best practices include building strong local partnerships, engaging regulators early, aligning with WHO/ICH harmonization efforts, and embedding patient affordability strategies into submissions.
Latest Updates and Strategic Insights
As of 2025, emerging market ATMP strategies are defined by new trends:
- Global–Local Hybrids: Multinationals adapting global dossiers while generating local RWE.
- Conditional Approvals: Increasing reliance on conditional licenses tied to registries and long-term monitoring.
- Digital Submissions: NMPA, CDSCO, and ANVISA accelerating adoption of eCTD platforms.
- Collaborative Manufacturing: Localized GMP partnerships to reduce costs and accelerate approvals.
- Expanded Patient Registries: Regulators requiring registry participation as a condition for market entry.
Strategically, RA professionals must combine global compliance expertise with local adaptability to succeed in emerging economies.
Conclusion
ATMP regulatory strategy in emerging markets requires balancing global standards with local realities. By aligning with CDSCO, NMPA, ANVISA, and MFDS frameworks, RA professionals can accelerate approvals while addressing affordability, infrastructure, and patient safety. In 2025 and beyond, success in emerging markets will depend on harmonized strategies, strong partnerships, and innovative models that expand patient access to advanced therapies.